Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
11082 | 943 | 25.4 | 63% |
Classes in level above (level 2) |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | MULTIPLE PRIMARY MALIGNANCIES | Author keyword | 25 | 70% | 2% | 21 |
2 | MULTIPLE PRIMARY MALIGNANT NEOPLASMS | Author keyword | 19 | 80% | 1% | 12 |
3 | MULTIPLE PRIMARY NEOPLASMS | Author keyword | 14 | 41% | 3% | 26 |
4 | SECOND PRIMARY CANCER | Author keyword | 12 | 30% | 4% | 35 |
5 | MULTIPLE PRIMARY CANCERS | Author keyword | 7 | 30% | 2% | 21 |
6 | MULTIPLE PRIMARY MALIGNANCY | Author keyword | 7 | 64% | 1% | 7 |
7 | SYNCHRONOUS CANCERS | Author keyword | 7 | 50% | 1% | 10 |
8 | SYNCHRONOUS PRIMARY CANCERS | Author keyword | 6 | 71% | 1% | 5 |
9 | TRIPLE CANCER | Author keyword | 6 | 71% | 1% | 5 |
10 | SECOND PRIMARY NEOPLASMS | Author keyword | 5 | 29% | 2% | 16 |
Web of Science journal categories |
Author Key Words |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | MULTIPLE PRIMARY MALIGNANCIES | 31 | 60% | 4% | 34 |
2 | MULTIPLE PRIMARY CANCERS | 17 | 29% | 5% | 49 |
3 | PRIMARY CANCERS | 14 | 38% | 3% | 30 |
4 | 2ND PRIMARY CANCER | 12 | 48% | 2% | 19 |
5 | SYNCHRONOUS CARCINOMAS | 12 | 86% | 1% | 6 |
6 | 2ND PRIMARY CANCERS | 11 | 22% | 5% | 45 |
7 | PRIMARY NEOPLASMS | 11 | 30% | 3% | 30 |
8 | PRIMARY MALIGNANCIES | 9 | 29% | 3% | 27 |
9 | PRIMARY MALIGNANT NEOPLASMS | 9 | 48% | 1% | 13 |
10 | EXTRAHEPATIC PRIMARY MALIGNANCIES | 8 | 100% | 1% | 5 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references |
% act. ref. to same field |
---|---|---|---|---|
Risk of second non-breast cancer after radiotherapy for breast cancer: A systematic review and meta-analysis of 762,468 patients | 2015 | 2 | 35 | 40% |
Second primary cancers after radiation for prostate cancer: A systematic review of the clinical data and impact of treatment technique | 2014 | 4 | 38 | 61% |
Multiple primary malignant neoplasms - Case report and a comprehensive review of the literature | 2003 | 48 | 11 | 100% |
Clinicopathological characteristics of patients with synchronous primary endometrial and ovarian cancers: A review of 43 cases | 2013 | 2 | 10 | 90% |
Synchronous tumours of the female genital tract | 2010 | 20 | 65 | 45% |
Risk of second primary cancer after breast cancer treatment | 2014 | 2 | 53 | 64% |
Synchronous Hepatocellular Carcinoma with Renal Cell Carcinoma: A Case Report and Review of Literature of Multiple Synchronous Primary Malignancies | 2013 | 1 | 3 | 100% |
Second primary cancers after radiation for prostate cancer: a review of data from planning studies | 2013 | 5 | 48 | 38% |
Secondary cancer after radiotherapy for prostate cancer: Should we be more aware of the risk? | 2007 | 38 | 31 | 65% |
Triple Synchronous Primary Gynecologic Carcinomas: A Case Report and Review of the Literature | 2011 | 3 | 14 | 79% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | CANC N CAROLINA | 1 | 50% | 0.1% | 1 |
2 | EPIDEMIOL SCREENING PREVENT | 1 | 50% | 0.1% | 1 |
3 | GRANTS CONTRACTS | 1 | 50% | 0.1% | 1 |
4 | HERBERT IRVING COMPREHENSIVE CANC | 1 | 50% | 0.1% | 1 |
5 | PATHO | 1 | 50% | 0.1% | 1 |
6 | PATHOL KONYA | 1 | 50% | 0.1% | 1 |
7 | REGISTRE GEN TUMEURS CALVADOS CANC PREVENT | 1 | 50% | 0.1% | 1 |
8 | REGISTRE TUMEURS DIGEST CALVADOS CANC PREVENT | 1 | 50% | 0.1% | 1 |
9 | SAKARYA EDUC HOSP | 1 | 50% | 0.1% | 1 |
10 | SECT LYMPHOMA MYELOMA | 1 | 50% | 0.1% | 1 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000141618 | SECONDARY LEUKEMIA//SECOND MALIGNANT NEOPLASM//THERAPY RELATED |
2 | 0.0000122465 | ERBA//COLLISION METASTASIS//ANTIBODIES TO THYROID PEROXIDASE |
3 | 0.0000115496 | ARLTS1//HERITABLE CANCER//FAMILIAL RISK |
4 | 0.0000106820 | PROSTATE SPARING//CYSTOPROSTATECTOMY//RADICAL CYSTOPROSTATECTOMY |
5 | 0.0000105139 | NARROW BAND IMAGING//GASTRIC TUBE CANCER//INTRAEPITHELIAL PAPILLARY CAPILLARY LOOP |
6 | 0.0000102875 | METACHRONOUS LUNG CANCER//MULTIPLE PRIMARY LUNG CANCER//INTRAPULMONARY METASTASIS |
7 | 0.0000089633 | CONTRALATERAL PROPHYLACTIC MASTECTOMY//BILATERAL BREAST CANCER//CONTRALATERAL BREAST CANCER |
8 | 0.0000061752 | INCIDENCE ESTIMATES//MED LIBERAL ARTS SCI//GUAM CANC REGISTRY |
9 | 0.0000058963 | PSYCHOSOCIAL BEHAV MED PROGRAM//ABSTINENCE RATES//UER LYON SUD CHARLES MERIEUX |
10 | 0.0000052285 | CA 242//PREOPERATIVE CEA LEVEL//POSTOPERATIVE SURVEILLANCE |